HCW Biologics Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

HCWB$0.95-6.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

	December 31,	December 31,
	2022	2023
ASSETS
Current assets:
Cash and cash equivalents	$22,326,356	$3,595,101
Short-term investments	9,735,930	—
Accounts receivable, net	417,695	1,535,757
Prepaid expenses	1,394,923	1,042,413
Other current assets	196,015	230,916
Total current assets	34,070,919	6,404,187
Investments	1,599,751	1,599,751
Property, plant and equipment, net	10,804,610	20,453,184
Other assets	333,875	56,538
Total assets	$46,809,155	$28,513,660
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities
Current liabilities:
Accounts payable	$1,226,156	$6,167,223
Accrued liabilities and other current liabilities	1,730,325	2,580,402
Total current liabilities	2,956,481	8,747,625
Debt, net	6,409,893	6,304,318
Other liabilities	14,275	—
Total liabilities	9,380,649	15,051,943
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock:
Common, $0.0001 par value; 250,000,000 shares authorized and 35,876,440 shares issued at December 31, 2022; 250,000,000 shares authorized and 36,025,104 shares issued at December 31, 2023	3,588	3,603
Additional paid-in capital	82,962,964	83,990,437
Accumulated deficit	(45,538,046)	(70,532,323)
Total stockholders’ equity	37,428,506	13,461,717
Total liabilities and stockholders’ equity	$46,809,155	$28,513,660

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.